Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity

被引：0
作者：
Moreau, P.
Coiteux, V.
Hulin, C.
Facon, T.
van de Velde, H.
Acharya, M.
Harousseau, J.
机构：
[1] CHU Hotel Dieu, Nantes, France
[2] Univ Hosp, Lille, France
[3] Univ Hosp, Nancy, France
[4] Johnson & Jonhson, R&D, Beerse, Belgium
[5] Johnson & Jonhson, R&D, Raritan, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8046
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and
    Moreau, P.
    Coiteux, V.
    Hulin, C.
    Facon, T.
    van de Velde, H.
    Acharya, M.
    Harousseau, J. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 158 - 158
  • [2] Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
    Moreau, Philippe
    Coiteux, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    van de Velde, Helgi
    Acharya, Milin
    Harousseau, Jean-Luc
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1908 - 1911
  • [3] COMPARATIVE EFFICACY OF SUBCUTANEOUS AND INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Skvortsova, N.
    Pospelova, T.
    Kovynev, I.
    Nechunaeva, I.
    HAEMATOLOGICA, 2014, 99 : 657 - 657
  • [4] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients:a Meta-analysis
    牟时代
    艾利莎
    秦铀
    胡豫
    CurrentMedicalScience, 2018, 38 (01) : 43 - 50
  • [5] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
    Mu, Shi-dai
    Al, Li-sha
    Qin, You
    Hu, Yu
    CURRENT MEDICAL SCIENCE, 2018, 38 (01) : 43 - 50
  • [6] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
    Shi-dai Mu
    Li-sha Ai
    You Qin
    Yu Hu
    Current Medical Science, 2018, 38 : 43 - 50
  • [7] SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A SINGLE INSTITUTION
    Lopez San Roman, I.
    De Miguel, D.
    Golbano, N.
    Diaz Morfa, M.
    Morales, D.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    Pinedo, B.
    HAEMATOLOGICA, 2012, 97 : 603 - 603
  • [8] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [9] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
    Zhang, Shilong
    Li, Jing
    Liu, Peng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
  • [10] Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma
    Moreau, Philippe
    Karamanesht, Ievgenii I.
    Domnikova, Natalia
    Kyselyova, Maryna Y.
    Vilchevska, Kateryna V.
    Doronin, Vadim A.
    Schmidt, Alexander
    Hulin, Cyrille
    Leleu, Xavier
    Esseltine, Dixie-Lee
    Venkatakrishnan, Karthik
    Skee, Donna
    Feng, Huaibao
    Girgis, Suzette
    Cakana, Andrew
    van de Velde, Helgi
    Deraedt, William
    Facon, Thierry
    CLINICAL PHARMACOKINETICS, 2012, 51 (12) : 823 - 829
12345